In line with this finding, a recent study that used SR9009 in prostate cancer cell lines revealed cytotoxic effects; however, further investigation did not prove involvement of REV-ERBs but rather activation of another NR, the liver X receptor α (LXRα) [65]. Here, NR1H3 is linked to prostate cancer.